State of Wyoming Has $40,000 Stock Holdings in Inhibrx Biosciences, Inc. $INBX

State of Wyoming cut its position in Inhibrx Biosciences, Inc. (NASDAQ:INBX) by 46.5% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,889 shares of the company’s stock after selling 2,513 shares during the period. State of Wyoming’s holdings in Inhibrx Biosciences were worth $40,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Inhibrx Biosciences in the fourth quarter worth $102,000. BNP Paribas Financial Markets acquired a new stake in Inhibrx Biosciences in the fourth quarter worth $128,000. Bank of America Corp DE acquired a new stake in Inhibrx Biosciences in the fourth quarter worth $191,000. XTX Topco Ltd acquired a new stake in Inhibrx Biosciences in the first quarter worth $237,000. Finally, Deutsche Bank AG acquired a new stake in Inhibrx Biosciences in the fourth quarter worth $302,000. 82.46% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently commented on INBX shares. Wall Street Zen upgraded shares of Inhibrx Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, August 17th. JMP Securities restated a “market perform” rating on shares of Inhibrx Biosciences in a report on Friday, August 22nd. One investment analyst has rated the stock with a Hold rating, According to data from MarketBeat, Inhibrx Biosciences currently has an average rating of “Hold”.

Inhibrx Biosciences Stock Down 6.5%

Inhibrx Biosciences stock opened at $27.65 on Thursday. The company has a market cap of $400.37 million, a P/E ratio of -2.61 and a beta of 0.33. Inhibrx Biosciences, Inc. has a 1-year low of $10.81 and a 1-year high of $30.23. The company has a fifty day simple moving average of $23.66 and a 200 day simple moving average of $16.79. The company has a current ratio of 4.98, a quick ratio of 4.98 and a debt-to-equity ratio of 1.45.

Inhibrx Biosciences (NASDAQ:INBX) last released its earnings results on Wednesday, August 13th. The company reported ($1.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.92) by $1.07. The business had revenue of $1.30 million during the quarter. Research analysts anticipate that Inhibrx Biosciences, Inc. will post 104.88 earnings per share for the current fiscal year.

Inhibrx Biosciences Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.